subcutaneous desferrioxamine daily infusion on iron balance in 23 thalassemia major children, aged 8-74 months, with transfusional iron accumulation less than 3.8 g at the outset of the trial.

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

The Insignis Syringe Infusion System is a robust ... These additional subcutaneous therapies include deferoxamine, factor, anti-nausea drugs, and monoclonal antibodies.

The Insignis Syringe Infusion System is a robust ... or Secondary Immune Deficiency and neuromodulation therapies. These additional subcutaneous therapies include deferoxamine, factor, anti-nausea ...